Table IV.
Results of model gene and IC50 value of therapeutics using the Pearson's correlation analysis based on Genomics of Drug Sensitivity in Cancer bladder cancer cells data.
| Gene | Drug | Correlation | P-value | Target | Pathway |
|---|---|---|---|---|---|
| EGR1 | AS601245 | 0.572 | 0.0171 | JNK | JNK and p38 signaling |
| EGR1 | PI-103 | 0.550 | 0.0218 | PI3K α, DNAPK | PI3K signaling |
| FOSL1 | QL-XI-92 | −0.559 | 0.0201 | DDR1 | RTK signaling |
| FOSL1 | GSK269962A | −0.56 | 0.0198 | ROCK1, ROCK2 | Cytoskeleton |
| FOSL1 | Bicalutamide | −0.581 | 0.0156 | Androgen receptor | Other |
| FOSL1 | MLN4924 | −0.584 | 0.0151 | NEDD8-activating enzyme | Other |
| FOSL1 | Olaparib | −0.585 | 0.0149 | PARP1, PARP2 | Genome integrity |
| FOSL1 | T0901317 | −0.596 | 0.0131 | LXR | Other |
| FOSL1 | STF-62247 | −0.598 | 0.0128 | Autophagy | Other |
| FOSL1 | TW 37 | −0.605 | 0.0118 | BCL-2, BCL-XL | Apoptosis regulation |
EGR1, early growth response protein 1; FOSL1, FOS-related antigen 1.